Drug Approval | February 19, 2022
US FDA to review Amylyx new drug application for AMX0035
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Recall does not include any metabolic deficiency nutrition formulas
ArisGlobal's industry-leading regulatory software chosen by top pharmaceutical company for IDMP preparation and global readiness
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Darolutamide is developed jointly by Bayer and Orion Corporation
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Dr. Raman has succeeded Victoria Richon
Subscribe To Our Newsletter & Stay Updated
